Macquarie Group
BCRX icon

Macquarie Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Macquarie Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30K Buy
+3,000
New +$27.1K ﹤0.01% 871
2024
Q4 		– Sell
-249,495
Closed -$1.9M – 1669
2024
Q3 		$1.9M Buy
+249,495
New +$1.9M ﹤0.01% 1245
2022
Q4 		– Sell
-5,019
Closed -$80K – 1787
2022
Q3 		$80K Sell
5,019
-1,302
-21% -$16.8K ﹤0.01% 1825
2022
Q2 		$67K Hold
6,321
– – ﹤0.01% 1976
2022
Q1 		$103K Sell
6,321
-1,984
-24% -$31.8K ﹤0.01% 1941
2021
Q4 		$115K Buy
8,305
+1,803
+28% +$23.9K ﹤0.01% 1892
2021
Q3 		$93K Sell
6,502
-2,103
-24% -$33.2K ﹤0.01% 2006
2021
Q2 		$136K Buy
8,605
+253
+3% +$3.44K ﹤0.01% 1880
2021
Q1 		$85K Sell
8,352
-1,580
-16% -$16.3K ﹤0.01% 1955
2020
Q4 		$74K Hold
9,932
– – ﹤0.01% 1941
2020
Q3 		$34K Buy
9,932
+3,200
+48% +$13.7K ﹤0.01% 2033
2020
Q2 		$32K Buy
+6,732
New +$26.9K ﹤0.01% 2033
2018
Q1 		– Sell
-1,800
Closed -$9K – 2186
2017
Q4 		$9K Buy
+1,800
New +$8.72K ﹤0.01% 2271
2016
Q2 		– Sell
-25,529
Closed -$72K – 1556
2016
Q1 		$72K Sell
25,529
-113,719
-82% -$504K ﹤0.01% 1457
2015
Q4 		$1.44M Buy
139,248
+1,806
+1% +$18K ﹤0.01% 1009
2015
Q3 		$1.57M Buy
137,442
+23,807
+21% +$318K ﹤0.01% 1033
2015
Q2 		$1.7M Buy
113,635
+3,243
+3% +$36.9K ﹤0.01% 1067
2015
Q1 		$997K Sell
110,392
-31,775
-22% -$329K ﹤0.01% 1155
2014
Q4 		$1.73M Buy
142,167
+43,616
+44% +$482K ﹤0.01% 1058
2014
Q3 		$964K Buy
98,551
+64,451
+189% +$790K ﹤0.01% 1170
2014
Q2 		$435K Buy
+34,100
New +$332K ﹤0.01% 1335

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Macquarie Group's BCRX Position: Q2 2026 in Review

Macquarie Group opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 3,000 shares worth $30K. The stake represents ﹤0.01% of the portfolio and ranks #871 among its holdings. This is a return to the name: Macquarie Group previously reported a position in BCRX as recently as Q3 2024.

Macquarie Group first reported a position in BCRX in Q2 2014 and has held it in 21 quarters since. The position peaked at $1.9M in Q3 2024. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Macquarie Group held 3,000 shares of BioCryst Pharmaceuticals worth $30K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Macquarie Group position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Macquarie Group's portfolio in Q2 2026, its #871 holding.
  • Macquarie Group first reported a position in BioCryst Pharmaceuticals in Q2 2014 and has held it in 21 quarters since.
  • Macquarie Group's BioCryst Pharmaceuticals position peaked at $1.9M in Q3 2024.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.